Abstract
Olanzapine, a lipophilic antipsychotic drug, has poor oral bioavailability due to hepatic first-pass metabolism. Solid Lipid Nanoparticles (SLNs) of Olanzapine were developed using lipids (Stearic acid and Glyceryl monostearate), soy lecithin, poloxamer 188 and charge modifier stearyl amine by microemulsion technique. The aim of this research was to find out whether the bioavailability of olanzapine can be improved by administering olanzapine SLN orally to Wistar rats. Area under curve was increased (up to 4-fold) and clearance was decreased when olanzapine entrapped in SLNs with stearylamine were administered orally compared with that of olanzapine suspension. The enhanced relative bioavailability by the SLNs formulation might be attributed to avoidance of first-pass hepatic metabolism by intestinal lymphatic transport, direct uptake of nanoparticles through the GI tract, increased permeability by surfactants, and decreased degradation and clearance. These results indicate that olanzapine can be loaded into solid lipid nanoparticles for improvement of its oral bioavailability.
Keywords: Bioavailability, cationic, microemulsion, olanzapine, oral delivery, solid lipid nanoparticles
Current Nanoscience
Title:Olanzapine Loaded Cationic Solid Lipid Nanoparticles for Improved Oral Bioavailability
Volume: 9 Issue: 1
Author(s): Sumeet Sood, Natarajan Jawahar, Kunal Jain, Kuppusamy Gowthamarajan and Subramania Nainar Meyyanathan
Affiliation:
Keywords: Bioavailability, cationic, microemulsion, olanzapine, oral delivery, solid lipid nanoparticles
Abstract: Olanzapine, a lipophilic antipsychotic drug, has poor oral bioavailability due to hepatic first-pass metabolism. Solid Lipid Nanoparticles (SLNs) of Olanzapine were developed using lipids (Stearic acid and Glyceryl monostearate), soy lecithin, poloxamer 188 and charge modifier stearyl amine by microemulsion technique. The aim of this research was to find out whether the bioavailability of olanzapine can be improved by administering olanzapine SLN orally to Wistar rats. Area under curve was increased (up to 4-fold) and clearance was decreased when olanzapine entrapped in SLNs with stearylamine were administered orally compared with that of olanzapine suspension. The enhanced relative bioavailability by the SLNs formulation might be attributed to avoidance of first-pass hepatic metabolism by intestinal lymphatic transport, direct uptake of nanoparticles through the GI tract, increased permeability by surfactants, and decreased degradation and clearance. These results indicate that olanzapine can be loaded into solid lipid nanoparticles for improvement of its oral bioavailability.
Export Options
About this article
Cite this article as:
Sood Sumeet, Jawahar Natarajan, Jain Kunal, Gowthamarajan Kuppusamy and Nainar Meyyanathan Subramania, Olanzapine Loaded Cationic Solid Lipid Nanoparticles for Improved Oral Bioavailability, Current Nanoscience 2013; 9 (1) . https://dx.doi.org/10.2174/1573413711309010007
DOI https://dx.doi.org/10.2174/1573413711309010007 |
Print ISSN 1573-4137 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6786 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Future of Neuroregenerative Therapy for Parkinson’s Disease
Current Tissue Engineering (Discontinued) Adult Neurogenesis and Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Common Neurogenetic Diagnosis and Meso-Limbic Manipulation of Hypodopaminergic Function in Reward Deficiency Syndrome (RDS): Changing the Recovery Landscape
Current Neuropharmacology Current Research on Opioid Receptor Function
Current Drug Targets Peak Treadmill Exercise Echocardiography
Reviews on Recent Clinical Trials Tako-tsubo Cardiomyopathy: A Review of the Literature
Current Cardiology Reviews Magnetic Resonance Imaging of Iron in Parkinsons Disease
Current Medical Imaging GluN2B/N-methyl-D-aspartate Receptor Antagonists: Advances in Design, Synthesis, and Pharmacological Evaluation Studies
CNS & Neurological Disorders - Drug Targets The Renin-Angiotensin System and the Neurodegenerative Diseases: A Brief Review
Protein & Peptide Letters Current Clinical Applications of Botulinum Toxin
Current Pharmaceutical Design Pharmacoproteomics Applications for Drug Target Discovery in CNS Disorders
Current Pharmacogenomics and Personalized Medicine GPCR Heteromers and their Allosteric Receptor-Receptor Interactions
Current Medicinal Chemistry Levodopa in Parkinson’s Disease: Current Status and Future Developments
Current Neuropharmacology Second-Generation Antipsychotic Agents: A Review of Safety Profiles
Current Psychiatry Reviews Strength and Weaknesses of Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease and Possible Detection of Overlaps with Frailty Process
CNS & Neurological Disorders - Drug Targets Clozapine Safety, 35 Years Later
Current Drug Safety Noradrenaline in Parkinsons Disease: From Disease Progression to Current Therapeutics
Current Medicinal Chemistry Monoamine Oxidase-B (MAO-B) Inhibitors in the Treatment of Alzheimer’s and Parkinson’s Disease
Current Medicinal Chemistry The Development of High-throughput Identification and Heterologous Expression of Valuable Peptides/Proteins
Current Proteomics Nitric Oxide Modulation of the Basal Ganglia Circuitry: Therapeutic Implication for Parkinson's Disease and Other Motor Disorders
CNS & Neurological Disorders - Drug Targets